passages: 2046
passages: document
passages: Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients : insights from the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . OBJECTIVES The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression . BACKGROUND Diabetes mellitus is associated with accelerated coronary atheroma progression . Pioglitazone slowed progression compared with glimepiride in this population . METHODS In all , 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE ( Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation ) study . Coronary atheroma progression was evaluated by serial intravascular ultrasound . The relationship between changes in biochemical parameters , percent atheroma volume , and total atheroma volume was investigated . RESULTS Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein . Significant correlations were observed between changes in percent atheroma volume and triglycerides ( r = 0.15 , p = 0.04 ) , triglyceride/HDL-C ratio ( r = 0.16 , p = 0.03 ) , and glycated hemoglobin ( r = 0.16 , p = 0.03 ) with pioglitazone , and changes in low-density lipoprotein cholesterol ( r = -0.15 , p = 0.05 ) , apolipoprotein B ( r = -0.16 , p = 0.04 ) , and apolipoprotein A-I ( r = -0.20 , p = 0.01 ) with glimepiride . Substantial atheroma regression , compared to progression , was associated with greater relative increases in HDL-C ( 14.2 % vs. 7.8 % , p = 0.04 ) , relative decreases in triglycerides ( -13.3 % vs. -1.9 % , p = 0.045 ) , triglyceride/HDL-C ratio ( -22.5 vs. -9.9 % , p = 0.05 ) , and decrease in glycated hemoglobin ( -0.6 % vs. -0.3 % , p = 0.01 ) . Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume ( p = 0.03 ) and total atheroma volume ( p = 0.02 ) . CONCLUSIONS Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients . This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease .
entities: 2047
entities: Intervention_Pharmacological
entities: pioglitazone
entities: 2048
entities: Intervention_Pharmacological
entities: pioglitazone
entities: 2049
entities: Intervention_Pharmacological
entities: Pioglitazone
entities: 2050
entities: Intervention_Pharmacological
entities: pioglitazone
entities: 2051
entities: Intervention_Pharmacological
entities: glimepiride
entities: 2052
entities: Intervention_Pharmacological
entities: Pioglitazone-treated
entities: 2053
entities: Intervention_Pharmacological
entities: pioglitazone
entities: 2054
entities: Intervention_Pharmacological
entities: glimepiride .
entities: 2055
entities: Intervention_Pharmacological
entities: pioglitazone-induced
entities: 2056
entities: Intervention_Pharmacological
entities: pioglitazone
entities: 2057
entities: Outcome_Physical
entities: triglyceride/high-density lipoprotein cholesterol ratio
entities: 2058
entities: Outcome_Physical
entities: coronary atherosclerosis
entities: 2059
entities: Outcome_Physical
entities: Coronary atheroma progression
entities: 2060
entities: Outcome_Physical
entities: changes in biochemical parameters
entities: 2061
entities: Outcome_Physical
entities: percent atheroma volume
entities: 2062
entities: Outcome_Physical
entities: total atheroma volume
entities: 2063
entities: Outcome_Physical
entities: high-density lipoprotein cholesterol ( HDL-C )
entities: 2064
entities: Outcome_Physical
entities: glycated hemoglobin
entities: 2065
entities: Outcome_Physical
entities: triglycerides
entities: 2066
entities: Outcome_Physical
entities: C-reactive protein
entities: 2067
entities: Outcome_Physical
entities: percent atheroma volume and triglycerides
entities: 2068
entities: Outcome_Physical
entities: triglyceride/HDL-C ratio
entities: 2069
entities: Outcome_Physical
entities: glycated hemoglobin
entities: 2070
entities: Outcome_Physical
entities: low-density lipoprotein cholesterol
entities: 2071
entities: Outcome_Physical
entities: apolipoprotein B
entities: 2072
entities: Outcome_Physical
entities: apolipoprotein A-I
entities: 2073
entities: Outcome_Physical
entities: HDL-C
entities: 2074
entities: Outcome_Physical
entities: triglycerides
entities: 2075
entities: Outcome_Physical
entities: triglyceride/HDL-C ratio
entities: 2076
entities: Outcome_Physical
entities: glycated hemoglobin
entities: 2077
entities: Outcome_Physical
entities: triglyceride/HDL-C
entities: 2078
entities: Outcome_Physical
entities: percent atheroma volume
entities: 2079
entities: Outcome_Physical
entities: total atheroma volume
entities: 2080
entities: Outcome_Physical
entities: triglyceride/HDL-C ratio
entities: 2081
entities: Outcome_Physical
entities: atheroma progression
entities: 2082
entities: Participant_Condition
entities: diabetic patients
entities: 2083
entities: Participant_Sample-size
entities: 360
entities: 2084
entities: Participant_Condition
entities: diabetic patients with coronary artery disease
entities: 2085
entities: Participant_Condition
entities: diabetic patients .
entities: 2086
entities: Participant_Condition
entities: diabetic patients with coronary artery disease .